Irinotecan dosing: Does the CPT in CPT-11 stand for "Can't Predict Toxicity"?

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 7-8

  Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CARBOXYLESTERASE; CYTOCHROME P450 3A4; CYTOTOXIC AGENT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DISEASE SEVERITY; DOSE CALCULATION; DRUG MECHANISM; DRUG RESEARCH; EDITORIAL; HEALTH CARE POLICY; HUMAN; PRIORITY JOURNAL; PROMOTER REGION;

EID: 0036138777     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.1.7     Document Type: Editorial

References (25)

1. Phase I and pharmacokinetic trial of weekly CPT-11
2. Camptothecin analogues: Topotecan and irinotecan
3. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective
4. Recommended guidelines for the treatment of chemotherapy-induced diarrhea
5. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer
6. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group
7. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
8. Genetic predisposition to the metabolism of irinotecan (CPT-11): Role of uridine diphosphate glucuronosyltransferase isoform 1Al in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
9. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients
10. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients
11. Metabolism of irinotecan (CPT-11) by CYP 3A4 and CYP3A5 in humans
12. Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters
13. Transport of topoisomerase I inhibitors by the breast cancer resistance protein: Potential clinical implications
14. Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea
15. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
16. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan
17. Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations
18. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues
19. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase
20. Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver
21. Pharmacogenetics of anticancer agents: Lessons from amonafide and irinotecan
22. Body surface area as a determinant of pharmacokinetics and drug dosing
23. Body-surface area as a basis for dosing of anticancer agents: Science, myth, or habit?
24. Gazing into a crystal ball: Cancer therapy in the post-genomic era